Novel Drug Combination to Treat Ewing Sarcoma

Ewing sarcoma is the second most common bone cancer in children and young adults but unfortunately is not very responsive to conventional chemotherapy. Novel combination of CDK inhibitor and PARP inhibitors have been found to be very effective in controlling growth of Ewing sarcoma cells and could be potential game changer in treatment of this disease.

Related Links